Weighting Longitudinal Data to Access Opioid Analgesia Tapering Outcomes among Patients with Co-occurring Chronic Pain and Substance Use Disorder

加权纵向数据以了解同时发生慢性疼痛和药物滥用障碍的患者阿片类镇痛逐渐减少的结果

基本信息

  • 批准号:
    10590322
  • 负责人:
  • 金额:
    $ 209.35万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-09-30 至 2025-09-29
  • 项目状态:
    未结题

项目摘要

Project Summary/Abstract In 2016, the Centers for Disease Control (CDC) released guidelines recommending non-pharmacologic treatment for chronic pain over use of opioid analgesia in response to rising overdose deaths and based on studies showing nonopioid and multidisciplinary approaches to pain contribute to functional and pain severity improvements. CDC guidelines also recommended opioid tapering for chronic pain patients with substance use disorder (SUD) and transition to medications for opioid use disorder (MOUD) for patients with co-occurring opioid use disorder (OUD). While opioid tapering has been widely implemented, few studies assess transitions to MOUD or multidisciplinary medicine use specifically among patients with chronic pain and co-occurring SUD. A primary reason for this limited knowledge is the population with chronic pain and co-occurring SUD is often relatively small in any given healthcare facility or system, and outcomes of interest may occur in low total numbers. Thus, a large database is required to conduct multifactorial research on outcomes associated with different approaches to opioid tapering, especially when evaluating whether trends hold among smaller demographic groups. To address this critical gap, our goal is to create weights for the Cerner Real-World© database, which includes electronic health records (EHR) data from over 100 million unique U.S. patients at 600 participating hospitals and clinics. Our hypothesis is that weighting the database will significantly enhance its representativeness in order to longitudinally assess the relationship between opioid tapering, multidisciplinary medicine, MOUD, and outcomes for chronic pain patients with co-occurring SUD. Our aims are to use American Hospital Association and U.S. Census data to create weights, stratified by hospital characteristics and adjusted by demographic variables, for analyzing the Cerner database (Aim 1); validate the weighting scheme in Aim 1 by comparing weighted estimates from the Cerner database to estimates from a well-established population (the Nationwide Inpatient Sample) for chronic pain, SUD, and overdose diagnoses and relevant multidisciplinary pain interventions for the years 2000-2025 (Aim 2); among patients with chronic pain and co-occurring OUD, examine how tapering opioid analgesics and transitioning to MOUD affects risk for overdose, suicide, and other hospitalizations, and assess how sex and race/ethnicity operate as effect modifiers in these relationships (Aim 3); and among patients with chronic pain and co-occurring SUD, examine how tapering opioid analgesics while using multidisciplinary pain treatment affects risk for overdose, suicide, and other hospitalizations, and assess how sex and race/ethnicity operate as effect modifiers in these relationships (Aim 4). This project will create a national database with validated weighting that will enable rigorous examination of opioid tapering approaches among patients with chronic pain and co-occurring SUD, which will subsequently improve knowledge of how multidisciplinary pain treatment and MOUD affect risks, while considering tapering-related inequities among demographic subpopulations.
项目总结/摘要 2016年,疾病控制中心(CDC)发布了建议非药物治疗的指南。 治疗慢性疼痛超过使用阿片类镇痛药,以应对过量死亡的增加,并基于 研究显示,非阿片类药物和多学科方法治疗疼痛有助于功能和疼痛严重程度 改进. CDC指南还建议使用药物的慢性疼痛患者逐渐减少阿片类药物 阿片类药物使用障碍(SUD)和过渡到阿片类药物使用障碍(MOUD)的患者合并阿片类药物 使用障碍(OUD)。虽然阿片类药物逐渐减少已被广泛实施,但很少有研究评估过渡到 MOUD或多学科药物特别用于慢性疼痛和并发SUD的患者。一 这种知识有限的主要原因是慢性疼痛和并发SUD的人群通常 在任何给定的医疗保健机构或系统中相对较小,并且感兴趣的结果可能发生在较低的总体 号码因此,需要一个大型数据库来对与下列因素相关的结果进行多因素研究: 阿片类药物逐渐减少的不同方法,特别是在评估较小的 人口群体。为了解决这一关键差距,我们的目标是为Cerner Real-World创建权重。 数据库,其中包括电子健康记录(EHR)数据,来自超过1亿独特的美国患者在600 参与的医院和诊所。我们的假设是,加权数据库将显着提高其 为了纵向评估阿片类药物逐渐减少、多学科 药物、MOUD和合并SUD的慢性疼痛患者的结局。我们的目标是利用美国 医院协会和美国人口普查数据来创建权重,按医院特征分层并进行调整 按人口统计变量,用于分析Cerner数据库(目标1);验证目标1中的加权方案 通过比较Cerner数据库的加权估计值和一个成熟的人口估计值( 全国住院患者样本),用于慢性疼痛、SUD和药物过量诊断以及相关多学科疼痛 2000-2025年的干预措施(目标2);在慢性疼痛和并发OUD患者中,检查 逐渐减少阿片类镇痛药和过渡到MOUD如何影响过量,自杀和其他风险 住院治疗,并评估性别和种族/民族如何在这些关系中作为效应调节因子(Aim 3);在慢性疼痛和并发SUD的患者中,检查逐渐减少阿片类镇痛药, 使用多学科疼痛治疗会影响药物过量、自杀和其他住院治疗的风险,并评估 性别和种族/民族如何在这些关系中起作用(目标4)。该项目将创建一个 具有经验证的权重的国家数据库,可对阿片类药物减量方法进行严格审查 在慢性疼痛和共同发生的SUD患者中,这将随后提高对如何 多学科疼痛治疗和MOUD影响风险,同时考虑到 人口亚群

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Fares Qeadan其他文献

Fares Qeadan的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 209.35万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 209.35万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 209.35万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 209.35万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 209.35万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 209.35万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 209.35万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 209.35万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 209.35万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 209.35万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了